Effective down-regulation of breast cancer resistance protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers

European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V
Hamidreza Montazeri AliabadiHasan Uludag

Abstract

Breast Cancer Resistance Protein (BCRP, ABCG2) is an efflux protein whose aberrant activity has been linked to multidrug resistance in cancer. Although siRNA delivery to down-regulate BCRP expression is promising to sensitize tumor cells against drugs, therapeutic use of siRNA requires effective carriers that can deliver siRNA intracellularly with minimal toxicity on target cells. This study explored the feasibility of special class of cationic polymers, namely lipid-substituted low molecular weight (2kDa) polyethyleneimine (PEI), as a carrier for siRNA-mediated BCRP down-regulation. Structure-function studies methodically evaluated the effect of a range of lipophilic substitutions for siRNA delivery and BCRP down-regulation. Our results showed a significant increase in siRNA delivery as a function of lipid substitution for a range of lipids ranging from C8 to C18. The BCRP silencing was correlated to siRNA delivery efficiency of the polymers, and effectively lasted for ∼5days after a single treatment of siRNA. BCRP down-regulation sensitized the drug-resistant cells to cytotoxic effect of mitoxantrone by a ∼14-fold decrease in the IC(50) value, whose effect was evident even after 14days. This study demonstrated the possibility...Continue Reading

References

Aug 1, 1995·Proceedings of the National Academy of Sciences of the United States of America·O BoussifJ P Behr
Jul 5, 1994·Proceedings of the National Academy of Sciences of the United States of America·A KumarB R Williams
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·L A DoyleD D Ross
Apr 29, 1999·Proceedings of the National Academy of Sciences of the United States of America·W T GodbeyA G Mikos
May 17, 2001·Bioconjugate Chemistry· Han SoS W Kim
Aug 23, 2001·Journal of Controlled Release : Official Journal of the Controlled Release Society·J H JeongT G Park
Mar 21, 2002·Nature Reviews. Cancer·Michael M GottesmanSusan E Bates
May 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Dimitri SemizarovStephen W Fesik
Oct 24, 2003·Annals of Hematology·M ScherrM Eder
Apr 2, 2005·Nature Reviews. Cancer·Michael DeanSusan Bates
Feb 23, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Won Jong KimSung Wan Kim
Mar 21, 2007·Journal of Cellular Biochemistry·Hui LvZhuchu Chen
Dec 13, 2007·Journal of Chemotherapy·A OnyenadumH P Kalofonos
Oct 22, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Young Tag KoVladimir P Torchilin
Jan 17, 2009·Neuroscience Letters·Aline MilaneChristine Fernandez
Apr 18, 2009·Toxicology and Applied Pharmacology·Anastasia MalekAchim Aigner
Apr 23, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maria L H VlamingAlfred H Schinkel
May 16, 2009·Current Cancer Drug Targets·Y C MayurN K Sathish
Aug 20, 2009·Mini Reviews in Medicinal Chemistry·L GattiP Perego
Aug 28, 2009·Expert Opinion on Drug Metabolism & Toxicology·Yi An, Weg M Ongkeko
Sep 4, 2010·Current Drug Metabolism·Zhanglin NiQingcheng Mao
Feb 16, 2011·Macromolecular Bioscience·Hamidreza Montazeri AliabadiHasan Uludağ

❮ Previous
Next ❯

Citations

Aug 3, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·A S GonçalvesE B Souto
Apr 30, 2014·Archives of Toxicology·Márton JaniPéter Krajcsi
May 31, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jing ZhangLeaf Huang
Aug 27, 2013·Drug Discovery Today·Tahereh FatemianEzharul Hoque Chowdhury
Jan 3, 2012·Biomaterials·Hamidreza M AliabadiHasan Uludağ
Jul 2, 2015·Pharmaceutical Research·Hamidreza Montazeri AliabadiHasan Uludağ
Dec 18, 2013·Nanomedicine : Nanotechnology, Biology, and Medicine·M VideiraR Gaspar
Sep 3, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Hamidreza Montazeri AliabadiHasan Uludağ
Oct 8, 2016·Biologicals : Journal of the International Association of Biological Standardization·Sanam AramiNasser Samadi
Dec 20, 2017·Cancer Gene Therapy·Oliver K AppelbeYoon Yeo
Feb 6, 2017·Macromolecular Bioscience·Daniel Nisakar Meenakshi SundaramHasan Uludağ
Mar 14, 2020·Journal of Experimental & Clinical Cancer Research : CR·Fang WangLiwu Fu
Jul 25, 2017·Scientific Reports·Meenakshi SharmaHamidreza Montazeri Aliabadi
Nov 3, 2020·Biomaterials Science·Terence TieuAnna Cifuentes-Rius
May 4, 2021·Chemical Reviews·Ramya KumarTheresa M Reineke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.